SRTS News & Events

Reports Q4 revenue $4.9M vs. $13.1M. "Following the publication of Current Procedural Terminology (CPT) codes for treating non-melanoma skin cancer with SRT in November - with a per-fraction increase of more than 300% versus prior delivery code - and despite a very tight subsequent selling window in the midst of multiple holidays, we shipped 14 systems in Q4 without any contribution from our historically largest customer, compared with six units in Q3 excluding shipments to that customer," said Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. "With dedicated reimbursement codes now in place, a strong balance sheet with no debt and significantly enhanced physician economics, we look forward to 2026 with greater business control, predictability, and optimism. FDA utilization increased significantly in 2025, with treatments up more than eight-fold versus 2024 and the number of patients treated up by more than 250%. In several cases, the new reimbursement rates served as catalysts for system purchases by FDA customers. International demand contributed meaningfully to the fourth quarter with shipments to China, and international markets remain an important component of our growth strategy. Looking to the first quarter of 2026, based on our current pipeline and order activity we expect shipments to exceed fourth quarter 2025 levels without any contribution from our historically largest customer. More broadly, 2026 represents a new operating environment for Sensus, one we intend to fully leverage including by hiring several new sales reps," Sardano continued. "With attractive reimbursement, a more diversified customer base, new international opportunities and a continued commitment to tight expense management, our objective is to achieve full-year profitability."

Sensus Healthcare announced that president Michael Sardano has been appointed to the additional role of chief commercial officer. In this newly created position, Sardano will direct the company's global sales, marketing and commercial strategy across its portfolio of SRT technologies, Sentinel software and related service models. These expanded responsibilities follow a recent reimbursement milestone from the Centers for Medicare & Medicaid Services, which established current procedural terminology codes specific to the use of superficial radiotherapy for non-melanoma skin cancer.

Reports Q3 revenue $6.9B, consensus $6.31B. "Earlier this week, CMS published first-ever dedicated CPT codes for SRT that represents compelling economics and reimbursement certainty. These new codes narrow the gap between office-based reimbursement and hospital outpatient rates, and by leveling the playing field, they enable strengthening adoption for SRT," said Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. "We are extremely excited for our physician partners and customers, and especially for their patients, as this is clear validation of our SRT technology for treating non-melanoma skin cancer and keloids for years to come, supported by strong reimbursement. Internationally, we are laying groundwork for broader expansion following our MDSAP certification and are seeing strong interest across select markets."